The busiest week for earnings kicks off on Monday, and investors are eyeing one group in particular: biotech.
The iShares Nasdaq Biotechnology Index ETF is on pace for its fourth-straight day of gains.
As bad headlines fade and Vertex rises, biotechnology is on the upswing, says Jefferies' Michael Yee.
Michael Yee, Jefferies managing director, discusses the run in biotech stocks as Vertex soars today.
Global fund managers see Nasdaq as the most crowded global trade, and they cut tech holdings in June and reduced U.S. stock allocations.
The “Fast Money Halftime Report” traders discuss their picks for the biotech sector as Vertex leads.
Interest in Scripps from Discovery revives a potential deal the two companies scrapped in 2014.
The biotech said its three-drug cocktails boosted a measure of lung function in patients with cystic fibrosis.
Some of the names on the move ahead of the open.
CNBC's Meg Tirrell reports Vertex's drug trials for cystic fibrosis were better than the Street expected.
Check out which companies are making headlines after the bell on Tuesday: UAL, VRTX, CSX & more
Vertex is attempting to expand treatment options to about 40 percent of cystic fibrosis patients.
CNBC's Meg Tirrell reports that Vertex's cystic firbrosis drugs improve lung function and shares are popping after hours.
CNBC's Meg Tirrell reports on Vertex reporting results from its 3-drug cystic fibrosis combinations.
Credit Suisse shared with clients the firm's strategic updates to biotechnology stock picks in its second-quarter earnings preview.
Jefferies analyst Michael Yee is positive on Biotechnology, detailing some of the firms favorite picks.
Private equity investor Royalty Pharma has built a $15B investment portfolio of top-selling drugs, The New York Times reports.
Which of the five big year-to-date winners has the best shot at continuing its rally through the rest of 2017?
CNBC's Landon Dowdy takes a look at the performance of the health-care sector.
Donald Trump plans to make good on drug pricing promises, but any action may be weeks away.